Check for updates

Original Article

Corresponding Author:

Javad Biabani-Ardakani; Yazd Reproductive Sciences Institute, Bouali Ave., Safaeyeh, Yazd, Iran. Postal Code: 8916877391 Tel: (+98) 9133528082 Email: javadbiabani@ssu.ac.ir

ORCID:

https://orcid.org/0000-0002-8903-9651

Received: 29 July 2024 Revised: 25 November 2024 Accepted: 19 December 2024

Production and Hosting by Knowledge E

© Nabi et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Editor-in-Chief: Aflatoonian Abbas M.D.

Gen Access

Radioprotective effect of omeprazole against testicular damage induced by ionizing radiation in mice: An experimental study

Ali Nabi^{1, 2} Ph.D., Azam Hassanpour Dehnavi³ Ph.D., Fahime Mazaheri^{1, 4} M.Sc., Nastaran Momeni⁵ M.Sc., Habib Nikukar^{4, 6} M.D., Ph.D., Mahdie Hemati⁷ Ph.D., Seyed Jalal Hosseinimehr⁸ Ph.D., Masoud Shabani⁹ M.D., Fatemeh Sadeghian-Nodoushan⁴ Ph.D., Javad Biabani-Ardakani^{1, 4, 6} Ph.D.

¹Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

²Andrology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

³Department of Anatomical Sciences and Cell Biology, Medical Faculty, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

⁴Biotechnology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

⁵Shahid Ramezanzadeh Radiation Therapy Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

⁶School of Advanced Medical Sciences and Technologies, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

⁷Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

⁸Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

⁹Department of Radiation Oncology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Abstract

Background: Radiation-induced normal tissue damage remains a major concern in radiotherapy, particularly affecting rapidly dividing cells, including those in reproductive tissues. Developing effective radioprotective agents to mitigate this damage is crucial for preserving fertility.

Objective: The radioprotective effects of omeprazole (OMP) were investigated in adult male mice undergoing external radiation.

Materials and Methods: In this experimental study, 36 adult male mice (30–35 gr, 6–8 wk old) were divided into 6 groups and orally administered OMP daily via oral gavage for 7 days before whole-body irradiation. On the 8th day, mice were subjected to a single 6 Gray dose of 6 megavoltage X-ray radiation. Blood samples were collected via cardiac puncture for testosterone level evaluation, while testicular specimens were harvested post-euthanasia for sperm parameters assessment and histological analysis. Additionally, spermatogenic cell density was evaluated.

Results: Irradiation of 6 Gray X-ray to the testis of mice significantly affected sperm count, progressive motility, DNA fragmentation, the number of sperm with normal morphology, and the number of immotile sperm. Furthermore, administration of OMP improved progressive motility, DNA fragmentation, and sperm viability. Histopathological findings showed irradiation led to severe testicular

atrophy with spermatogenic arrest and abnormal cytoarchitecture vacuolation and interstitial edema, while OMP treatment reversed relative radiation toxicity, especially in the 50 mg OMP treatment group. **Conclusion:** In conclusion, OMP could act as an effective radioprotector against testicular damage following X-ray irradiation in an animal model. Further studies are needed to investigate OMP potential in protecting human testis tissue.

Keywords: Omeprazole, Ionizing radiation, Radioprotective, Radiotherapy, Testicular.

1. Introduction

Radiotherapy has consistently proven to be a highly effective method for treating cancer, with approximately 50% of cancer patients undergoing radiotherapy at various stages of their therapeutic management, both for curative and palliative aims (1). The radiation used in radiation therapy is recognized as ionizing radiation, as it can produce electrically charged ions and release energy within cellular structures as it passes through. The fundamental objective of radiation therapy is to maximize the radiation dose to abnormal cancer cells while minimizing exposure to normal cells, which are adjacent to cancer cells or in the path of radiation.

However, through the delivery of high radiation doses to the tumor sites, there are concerns about damage to the surrounding healthy vital organs (2), and they can cause side effects with varying severity and duration (3). Among various body tissues, the testis is one of the most radiosensitive ones. In humans, doses as low as 0.1 Gray (Gy) leads to a temporary reduction in the number of spermatogonia, and a dose of 0.15 Gy will result in temporary infertility. After a radiation dose of 2 Gy, azoospermia occurs for several years, and permanent azoospermia is the result of a dose in the range of 6-8 Gy with 2 Gy per session (4). Recovery is very slow in men. It takes a long time for sperm production to recover, over 6 months after a dose of 1.0 Gy and possibly more than

2 yr after 6.0 Gy. Even after sperm count recovers, fertility issues or miscarriages can happen due to low-quality or genetic anomalies (5).

Efforts are being made to reduce the side effects of radiation therapy. One approach is improving the precision of radiation delivery with techniques like intensity-modulated radiotherapy and proton therapy (6). These methods help but cannot completely protect healthy tissues near the tumor. Another approach involves using compounds, either synthetic or naturally occurring, to help healthy tissues better respond to radiation (7).

There are 4 main groups of such agents: synthetic (8), immunomodulator (9, 10), natural (11, 12), and herbal (13). These agents have various abilities, like reducing the damage of free radicals, acting as antioxidants, stimulating the immune system, and toxicity reduction properties (8). Several recent studies have focused on repurposing current medicine as radioprotective agents. A good choice should protect most organs, be easy to use, have minimal side effects, be stable for a long time, and be compatible with other medications the patient might be taking. Among various candidates, omeprazole (OMP), a proton pump inhibitor (PPI) frequently used to treat gastrointestinal disorders, looks promising because of its antioxidant and anti-inflammatory properties. Studies have shown that PPIs have a protective effect on normal tissues in the irradiated area by reducing the inflammatory response (14). Moreover, in vivo studies demonstrate the use of antioxidants as effective radiation protectors (15–17). In addition to the above properties, OMP's low risk of toxicity and widespread availability make it a good option for radiation protection.

While findings these look promising, there remains a need for a comprehensive understanding of its mechanisms of action, optimal dosage, and timing of administration. To address these questions, this study aims to evaluate OMP's radioprotective properties against testicular damage induced by ionizing radiation in mice. The result of this study holds the promise of providing valuable insights into whether OMP could serve as a viable treatment for radiation-induced testicular damage in humans, as well as the optimal protocols for its administration.

2. Materials and Methods

2.1. Animals

This experimental study was performed in Yazd Reproductive Sciences Institute, Yazd, Iran from January to December 2023. A total of 36 adult male mice (30–35 gr body weight, 6–8 wk old) were obtained from the Animal Research Center of Biotechnology, Yazd Reproductive Sciences Institute, Yazd, Iran, and were acclimatized for a week before the study. Animals were kept based on guidelines for the care and use of laboratory animals in Iran in standard conditions of 12-hr light/dark cycle with relative humidity (50 \pm 10%) and temperature (26 \pm 2°C). Mice received standard food and water and were kept in polypropylene cages.

2.2. Study design

Animals were randomly divided into 6 groups (n = 6/each):

G1 (Control): Mice received a 0.5% solution of carboxymethyl cellulose containing 0.9% NaCl.

G2 (Radiation): Mice were only exposed to total body radiation with a dose of 6 Gy.

G3 (OMP 30 mg/kg): Mice received 30 mg/kg daily for 7 days.

G4 (Radiation + OMP 30 mg/kg): Mice were pre-treated with OMP at a dose of 30 mg/kg daily for 7 days, and on day 8, they were exposed to 6 Gy whole-body irradiation.

G5 (OMP 50 mg/kg): Mice received 50 mg/kg daily for 7 days.

G6 (Radiation + OMP 50 mg/kg): Mice were pre-treated with OMP at a dose of 50 mg/kg daily for 7 days, and on day 8, they were exposed to 6 Gy whole-body irradiation.

Animals in all groups were killed on day 15 of the study (1 wk after irradiation) and sperm parameters, histopathological, and serum testosterone assays were performed (Figure 1).

2.3. Sample size

The sample size was determined based on previous studies (18, 19).

2.4. Drug preparation and irradiation

OMP (Tehran Chemistry Pharmaceutical Co., Iran) was freshly prepared in a 0.5% solution of carboxymethyl cellulose containing 0.9% NaCl and administered daily with 2 doses by oral gavage a week prior to whole-body irradiation. On day 8 of the study, mice were placed in a plexiglass phantom. They were irradiated with a 6 megavoltage X-ray beam produced by a radiotherapy machine (Linear accelerator, Siemens, Oncor, Germany) at a distance (source to skin distance) of 100 cm at a single dose of 6 Gy whole-body studies (20).

2.5. Specimen collections

Mice from each group were fully anesthetized with an intraperitoneal injection of a mixture of ketamine (50 mg/kg, Alfasan, Netherlands) and xylazine (5 mg/kg, Alfasan, Netherlands), and blood samples were obtained from their hearts using a syringe to measure testosterone, and they were allowed to clot. The serum was centrifuged at 3000 rpm for 15 min and stored at -20°C for evaluating the testosterone. To collect testicular samples, immediately after euthanizing, the abdominal wall was opened, and then both testicles and epididymis were removed from the scrotum, and their weights were recorded. Testicles were placed in a 10% formalin fixative for histological section preparation.

2.6. Sperm parameters evaluation

2.6.1. Sperm preparation and treatment

For sperm collection, the left and right epididymis were dissected and washed with saline; then, the caudal part of it was used for the assessment of sperm parameters. For sperm preparation, the Hams F10 medium supplemented with albumin was pre-warmed at 37° C, CO₂ 6% in the incubator. The epididymis caudal part was minced and incubated in media (5 ml) for 15 min.

2.6.2. Measurement of sperm count

10 μ l of sperm sample was placed on the Makler chamber slide, and sperm number in vertical and horizontal squares was counted. Then, the mean of 2 was recorded and expressed as 10⁶/ml.

2.6.3. Measurement of sperm motility

For sperm motility assessment, 10 μl of sperm sample was placed on a pre-warmed

slide, and 100 sperm were evaluated at different microscopic fields by phase contrast microscope (Olympus, Japan) with ×400 magnifications. Progressive motile spermatozoa, non-progressive motile spermatozoa and immotile spermatozoa percentage were reported based on the World Health Organization 2021 instructions.

2.6.4. Measurement of sperm viability

Sperm viability was measured by eosin-nigrosine staining. The sperm sample (10 µl) was mixed with the same volume of eosin-nigrosine dye. The smear of each sample was prepared on slides, and after drying in air, the sperm viability was evaluated by phase contrast microscope (Olympus, Japan) under ×1000 magnification. Sperm with no color was counted as viable, and pink or red ones were considered dead sperm.

2.6.5. Measurement of sperm morphology

Diff-quik staining kit (Ideh Varzan Farad Co., Iran) was provided to assess sperm morphology. A smear was prepared, and a staining procedure was performed based on kit instructions. The morphology of 200 sperm were assessed at a magnification of ×1000 by light microscopy (World Health Organization, 2021). The percentage of normal spermatozoa was recorded.

2.7. Measurement of sperm deoxyribonucleic acid (DNA) integrity

A Halo sperm kit (SDFA kit, Ideh Varzan Farad, Tehran, Iran) was provided to measure sperm DNA fragmentation. Briefly, a sperm sample (50 μ I) was added to low-melting agarose. Then, 20 μ I of the mixture was placed on a precoated slide and spread by using a coverslip. After that slides were kept at 4°C for 5 min. Coverslips were removed, and staining procedures were carried out based on kit protocol instructions. Then, light microscopy with a magnification of ×1000 was applied to evaluate the DNA statue of 200 sperm. Halo size was the indicator of DNA fragmentation rate. Large or medium size of halo showed no DNA fragmentation, and sperm with small or no halo showed fragmented DNA.


2.8. Serum testosterone level


The serum testosterone level was assessed using a commercial enzyme-linked immunosorbent assay kit (ZellBio, GmbH, Germany, Cat No. ZB-10260C-M9648) following the manufacturer's instructions. Optical density at a wavelength of 450 nm with a reference wavelength of 620–630 nm was measured using an enzyme-linked immunosorbent assay reader (21).

2.9. Histopathological analysis (light microscopy studies)

At the end of the experiment, the testis specimens were removed and then fixed in a 10% buffered formalin solution for 3 days, respectively, at room temperature. After fixation, tissue samples were dehydrated in ascending grades of alcohol (ethanol) and then cleared in xylene, which was then embedded in paraffin wax. The tissues were processed for paraffin blocking out, and then sections were cut with a rotary microtone (RM 2525, Leica Biosystems, Germany). Afterward, 5 µm thick sections, mounted on glass slides, were deparaffinized and rehydrated through a descending grade of alcohol and water to be stained with hematoxylin and eosin (H&E) (Merck GmbH, Darmstadt, Germany) staining method.

For histopathological studies, the stained slides were evaluated in random order by a histologist, who was blinded to the experimental groups to evaluate spermatogenesis and histopathological changes. The testicular tissue was examined under a light microscope (Olympus, Tokyo, Japan), with the magnification of ×40, ×100, and ×400 and photographed using a Zeiss Microscopy system.





2.10. Ethical Considerations

All the experimental procedures used in the present study were approved by the Animal Ethics Committee of the Shahid Sadoughi University of Medical Sciences, Yazd, Iran (Code: IR.SSU.AEC.1401.015). The animal experimental protocols were supported by the guidelines for care and use of laboratory animals in Iran.

2.11. Statistical Analysis

Statistical analysis for the obtained data was performed using version 19 Statistical Package for the Social Sciences (SPSS) (Chicago, IL). All the data normally distributed are presented as the mean \pm standard deviation (SD). Analysis of variance (ANOVA), one-way ANOVA, and Tukey's post-tests were used to eliminate any outliers from the normal data distribution. Statistically significant differences were accepted as p < 0.05.

3. Results

3.1. Effects of OMP on sperm parameters (count, motility, viability, and morphology)

Radiation significantly decreased sperm count compared to the control group (p < 0.05). Administration of OMP did not remarkably change sperm count. Radiation caused significant decreases in the percentage of progressive motile spermatozoa. OMP 30 mg/kg (OMP 30), OMP 50 mg/kg (OMP 50), Radiation+OMP 30 mg/kg (R+OMP 30) and R+OMP 50 mg/kg (R+OMP 50) groups resulted in significant increases in the percentage of progressive motile spermatozoa compared to the radiation group (p < 0.01). Moreover, the progressive motile spermatozoa percentage noticeably increased in the control group compared to the radiation group (p < 0.001). The percentage of nonprogressive motile spermatozoa did not significantly alter among different groups. Radiation significantly decreased sperm morphology compared to the control group (p < 0.05). Radiation resulted in significant decreases in the percentage of viable spermatozoa compared to the control group (p < 0.001). A significant increase was observed in viable spermatozoa percentage in the control, OMP 30, OMP 50, and R+OMP 50 groups compared to the radiation group (p < 0.001) (Table I).

3.2. Effects of OMP on sperm DNA integrity

The results of independent *t* test showed that the percentage of sperm with fragmented DNA significantly increased in the radiation group compared to the control and R+OMP 30 groups (p < 0.001, p < 0.05). In addition, all OMP groups significantly decreased the percentage of DNA-fragmented sperm in comparison with the radiation group (p < 0.001) (Table I).

3.3. Serum testosterone level

Despite these obvious differences in the serum testosterone levels between the control and radiation groups at 1 wk after irradiation (on day 15 of the study), the serum testosterone levels were not significantly different among the groups (Figure 2).

3.4. Histopathological findings

Considering the histopathological analysis light microscopic examination of the testicular tissue sections, results in the control group showed normal seminiferous tubules with the complete process of the spermatogenic series in stepwise stages of development (type A and B spermatogonia, primary and secondary spermatocyte, spermatid, and spermatozoa) and Sertoli cells.

The multiple seminiferous tubules were separated by intervening connective tissue containing blood vessels, Leydig cells, and other components of connective tissue. There was a normal height of the germinal epithelium with normal cellular associations located in invaginations or dilations between Sertoli cells. In contrast to the control group, results showed that ionizing radiation causes negative effect on the architecture of testes leading to a potent side effect on qualitative and quantitative changes.

Testicular tissue slides of the radiation group exhibited widespread edematous areas accompanying severe testicular atrophy with spermatogenic arrest in the developmental stage and abnormal cytoarchitecture vacuolation. Further, the germinal epithelium was thinner and showed a decrease in height in the radiated mice. The seminiferous tubules had an irregular size and distorted shape with depleted spermatogonia, spermatocytes, and reduction in spermatozoa density. Also, there were some detached, dense irregular nuclei, retained elongated spermatids, and displacement of Sertoli cell (Figure 3).

Connective tissue containing dilated and congested vessels and Levdig cells were decreased between the seminiferous tubules of ionizing radiation mice. As compared to the ionizing radiation group, examination of the radiated testis with OMP treatment groups (30 and 50 mg dosages) revealed the presence of a decrease in disorganization in the seminiferous tubules with resumption of different stages of the spermatogenic series and relatively showed normal cellular associations and counts. Furthermore, Sertoli cells increased in the seminiferous tubules of treated mice, and some of the seminiferous tubules had a normal height of germinal epithelium. Meanwhile, in some areas, there was tubal vacuolation with abnormal cytoarchitecture and reduction in spermatids or completely depleted spermatozoa; this condition was seen more in the 30 mg OMP treatment group compared to the 50 mg treatment group. Although treatment with OMP reversed the testes histological parameters damage compared to the ionizing radiation group, the interstitial spaces among the seminiferous tubules had increased compared to normal testis. They observed scanty connective tissue containing Leydig cells with interstitial edema, especially in the 30 mg OMP treatment group (Figure 4).

Parameters	Control	Radiation	OMP 30	OMP 50	R+OMP 30	R+OMP 50	P-value
Count (10 ⁶)	57.8 ± 25.4 [#]	29.60 ± 14.06*	49.40 ± 8.2	52 ± 10.7	38.17 ± 12.6	51 ± 8.7	0.04
Progressive motility (%)	47.33 ± 3.5 ^{###}	35 ± 3.74***	$44.4 \pm 2.4^{\#\#}$	41.8 ± 1.6*##	40.6 ± 1.9*##	41.1 ± 1.7* ^{##}	< 0.001
Nonprogressive motility (%)	9.8 ± 2.04	12 ± 3.1	9.4 ± 1.1	9.2 ± 1.5	8.8 ± 1.4	9.5 ± 1.6	0.17
Immotile (%)	42.8 ± 3.9 ^{###}	$53 \pm 4^{***}$	$46 \pm 2.3^{\#}$	49 ± 1.8	48 ± 2.7	49 ± 4.1*	< 0.001
Morphology (%)	9.17 ± 1.4 ^{##}	4.8 ± 1.3*	8 ± 2.4	7.8 ± 3.03	7.1 ± 1.9	6.8 ± 0.75	0.02
Viability (%)	70.0 ± 4.0 ^{###}	56.4 ± 5.45***	66.6 ± 1.14 ^{###}	67.20 ± 2.28 ^{###}	62.17 ± 4.02*	66.5 ± 1.87 ^{###}	< 0.001
DNA fragmentation (%)	17.3 + 2.16###	28.4 + 3.9***	21.0 ± 0.7 ^{###}	19.8 + 0.8###	22.17 ± 1.16*###	20.33 + 1.04###	< 0.001

Table I. Sperm parameter and DNA integrity in different groups

Data are presented as Mean \pm SD, One-way ANOVA and Tukey's post-tests, *P < 0.01, ***P < 0.001 significant differences vs. control group. *P < 0.05, ***P < 0.01, ****P < 0.01, ****P < 0.001 significant differences vs. radiation group. OMP: Omeprazole, R+OMP: Radiation+Omeprazole




Figure 2. Serum testosterone level, R: Radiation, OMP: Omeprazole.




Figure 3. Photomicrograph testis sections in the A) Control group and the B) Ionizing radiation group. Normal testicular structure and spermatogenesis are seen in the control mice group. In contrast, nearly all lineage of spermatogenic cells were arrested, and the spermatozoa were completely depleted of the seminiferous tubules (ST). They observed several vacuolations and widespread edematous areas in the ionizing radiation group. Seminiferous tubules, spermatogonia (blue arrow), spermatocytes (yellow arrow), Spermatid (white arrow), Sertoli cell (green arrow), Leydig cells (red arrow), edematous areas (asterism mark **), vacuolation (flower punctuation mark *) (Magnification: ×400, H&E staining, Scale bar: 50 µm).




Figure 4. Radioprotective effect of OMP on mice spermatogenesis system induced by ionizing radiation. A) Control, B) Radiation, C) OMP 30 mg treatment, D) OMP 50 mg treatment, control group showed normal seminiferous tubules with the complete process of the spermatogenic series. Meanwhile, irradiation led to severe testicular atrophy with spermatogenic arrest and abnormal cytoarchitecture vacuolation and interstitial edema, while OMP treatment reversed relatively radiation toxicity, especially in OMP 50 mg treatment group (magnification: ×100, H&E staining, scale bar: 100 µm).

4. Discussion

The main findings of this study were: I) radiation reduced sperm count, progressive motility, and the percent of sperm with normal morphology; II) radiation increased the number of immotile sperm and DNA fragmentation; III) OMP has a radioprotective effect on sperm's progressive motility; viability and DNA fragmentation; IV) radiation caused no significant changes in serum testosterone level, V) OMP showed a protective effect on histopathology of irradiated testis tissue.

Despite the widespread use of radiation for diagnosis and treatment in various medical domains, it can cause adverse effects on normal tissues. Among these, the testis represents one of the most radiosensitive tissues in animals (22). In contrast with the increasing incidence of cancer survivors, the importance of testis protection is highly valued, particularly in those of reproductive age. Several studies have shown the acute and late effects of radiation on sperm parameters. In the present study, the mean total sperm count reduced from $115.9-30.0 (\times 10^6)$ after radiation exposure. The progressive motility also decreased considerably from 31.6-11.8%, which was in accordance with another study in this area. Moreover, there was a remarkable decrease in the average frequency of sperm with normal morphology and motile sperm in the present study, which was consistent with the result of a study (23).

Sperm DNA fragmentation following pelvic irradiation is widely studied. It is well known that sperm chromatin differs structurally and functionally from somatic cell chromatin: it lacks nucleosome organization. Sperm DNA is significantly more compacted, with 6-fold higher density and 40-fold less volume compared to somatic cell DNA. Despite the compact packaging and antioxidant protection from seminal fluid, DNA damage can still occur in both developing and mature sperm (24). The findings of an article show 365% more DNA damage after 4 Gy irradiation than the control group (25). Also, our results showed just over an 11% rise in DNA damage in the radiation group compared to the control.

In a study of 2 Gy irradiation, the authors reported a decrease in spermatogenic cells and thinning in the germinal epithelium wall resulting from exposure to ionizing radiation (26). In agreement with a previous study, our findings revealed a spermatogenic arrest in the developmental stage and thinning of germinal epithelium in addition to a decrease in the height of some seminiferous tubules in the radiation group. Additionally, severe testicular atrophy and widespread edematous were observed. Moreover, disorganization and abnormal cytoarchitecture vacuolation were seen. It is widely recognized that radiation has a late adverse effect on serum testosterone levels and can decrease serum testosterone levels significantly during months or years after the end of radiation therapy (27-29). However, there are rare studies that investigate the serum testosterone levels in an acute phase after radiation therapy. In a study, no significant decrease was observed in serum testosterone levels after stereotactic body radiation therapy in prostate cancer (30).

Additionally, another study reported no changes in testosterone levels after proton therapy was statistically significant at the treatment completion point. In the present study, we found no significant change in serum testosterone levels between the control and radiation groups on day 15 of the study. Both dosages of OMP did not have a statistically significant effect on serum testosterone levels. One of the limitations of this study is the relatively small sample size of serum specimens, which may not be sufficient to support the results of statistically significant differences in testosterone tests.

PPIs, commonly used to treat acid-related disorders, have been studied for their potential radioprotective properties. The radioprotective mechanism of PPIs involves several pathways that can reduce radiation-induced damage to healthy tissues: reduction of oxidative stress (ionizing radiation generates reactive oxygen species [ROS]) that cause oxidative damage to cellular components, including DNA, lipids, and proteins. PPIs like OMP, lansoprazole, and pantoprazole have been found to exhibit antioxidant properties (30, 31) and anti-inflammatory effects. PPIs have been shown to inhibit pro-inflammatory cytokines (such as tumor necrosis factor-alpha and interleukin-6) (32). The apoptosis inhibition of PPIs can protect healthy cells by inhibiting radiation-induced apoptosis. A study suggest that PPIs may enhance DNA repair mechanisms, which is vital in minimizing radiation-induced genomic damage. Therefore, OMP as a PPI, due to its antioxidant and anti-inflammatory properties, is a suitable choice for radioprotective studies (14).

To the best of our knowledge, no study evaluates the effectiveness of OMP against testicular damage. In this study, both dosages of 30 and 50 mg/kg of OMP significantly increased the sperm's progressive motility parameter compared with the radiation group (p < 0.01). In addition, there was a considerable rise in sperm viability at both doses of OMP in comparison with the radiation group (p < 0.05). Moreover, DNA fragmentations were significantly lower in G4 (R+OMP 30 mg/kg) than in the radiation group (p < 0.001).

Radiation can cause several histopathological changes in testicular tissue, spermatogenic cell damage and reduction in spermatogenesis due to damage to spermatogonia and spermatocytes, testicular atrophy, and tubular damage to seminiferous tubules, including fluid accumulation and several vacuolations in the interstitial spaces (6).

All of this evidence can be seen in the present study. The histopathological results showed that ionizing radiation caused a significant alteration in the testicular structure parameters, as evident nearly all lineage of spermatogenic cells were arrested, and the spermatozoa were completely depleted of the seminiferous tubules and were observed in several vacuolation and widespread edematous areas. Morphometric examination of the testes showed that OMP could preserve seminiferous tubules of testes in mice that received irradiation. In this study, data showed that the most protective effect of OMP is at a dose of 50 mg/kg in the testes exposed to irradiation.

Radiation generates ROS, leading to oxidative stress and cellular damage (6). OMP has been shown to scavenge free radicals, reduce oxidative stress and enhance the activity of endogenous antioxidant enzymes such as superoxide dismutase and catalase, which neutralize ROS. OMP can modulate the release of these cytokines, thereby reducing inflammation and inhibiting the nuclear factor kappa B signaling pathway, which plays a key role in inflammation and cell survival after radiation exposure (32). Testicular tissue from OMP-treated, irradiated animals shows less structural damage and improved spermatogenesis compared to untreated, irradiated group.

OMP exhibits potential as a radioprotective agent for testicular tissue by mitigating oxidative stress, reducing inflammation, and enhancing cellular survival.

5. Conclusion

The findings of this study showed that OMP has a radioprotective effect on sperms progressive motility and viability. In addition, administration of OMP can reduce sperms DNA fragmentation. Furthermore, this study marks the first writing of the radioprotective effects of OMP against testicular damage. This study's findings are promising to be used in clinical practices as radioprotective agent in radiotherapy. Nevertheless, considering the findings of this study, further investigations are warranted, and additional human studies are necessary to elucidate the protective role of OMP in mitigating radiation-induced acute testicular toxicity.

Data Availability

Data supporting the findings of this study are available upon reasonable request from the corresponding author.

Author Contributions

J. Biabani-Ardakani, S.J. Hosseinimehr, A. Nabi, A. Hassanpour Dehnavi, and H. Nikukar contributed to the conception and design of the work and interpretation of data. J. Biabani-Ardakani, F. Mazaheri, A. Hassanpour Dehnavi, M. Shabani, and F. Sadeghian-Nodoushan carried out the drug preparation, irradiation, specimen collections, and histopathological analysis. M. Hemati carried out the serum testosterone test. A. Nabi carried out the sperm parameters evaluations. Drafting of the manuscript: J. Biabani-Ardakani, A. Nabi, A. Hassanpour Dehnavi, and N. Momeni. All authors read and approved of the final manuscript.

Acknowledgments

This study was financially supported by Shahid Sadoughi University of Medical Sciences, Yazd, Iran (Code: 13312). We confirm that we did not use AI in this context and provide information and support independently, without AI influence.

Conflict of Interest

The authors declare that there is no conflict of interest.

References

- Joiner MC, van der Kogel AJ, Steel GG. Introduction: The significance of radiobiology and radiotherapy for cancer treatment. In: Joiner MC, van der Kogel A. Basic clinical radiobiology. 4th Ed. London: CRC Press; 2018.
- [2] Keall PJ, Brighi C, Glide-Hurst C, Liney G, Liu PZ, Lydiard S, et al. Integrated MRI-guided radiotherapy -opportunities and challenges. *Nat Rev Clin Oncol* 2022; 19: 458–470.
- [3] Wang K, Tepper JE. Radiation therapy-associated toxicity: Etiology, management, and prevention. CA Cancer J Clin 2021; 71: 437–454.
- [4] Kubikova E, Klein M, Svitok P, Stefanic J, Benus R, Polak S, et al. Fertility maintenance in male oncological patients: Current state and future perspectives. *Bratisl Lek Listy* 2019; 120: 485–493.
- [5] Okada K, Fujisawa M. Recovery of spermatogenesis following cancer treatment with cytotoxic chemotherapy and radiotherapy. *World J Mens Health* 2019; 37: 166–174.
- [6] Bourgier C, Levy A, Vozenin M-C, Deutsch E. Pharmacological strategies to spare normal tissues from radiation damage: Useless or overlooked therapeutics? *Cancer Metastasis Rev* 2012; 31: 699–712.

- [7] Johnke RM, Sattler JA, Allison RR. Radioprotective agents for radiation therapy: Future trends. *Future Oncol* 2014; 10: 2345–2357.
- [8] Kaur R, Lang DK, Singh H, Arora A, Garg N, Saini B. Repurposing of various current medicines as radioprotective agents. *Anticancer Agents Med Chem* 2023; 23: 1104–1121.
- [9] Patchen ML. Immunomodulators and cytokines: Their use in the mitigation of radiation-induced hemopoietic injury. In: Bump EA, Malaker K. Radioprotectors (chemical, biological, and clinicl prespectives). Boca Raton: CRC Press; 2021.
- [10] Liu L, Liang Z, Ma S, Li L, Liu X. Radioprotective countermeasures for radiation injury. *Mol Med Rep* 2023; 27: 66.
- [11] Shivappa P, Bernhardt GV. Natural radioprotectors on current and future perspectives: A mini-review. J Pharm Bioallied Sci 2022; 14: 57–71.
- [12] Zhang Y, Huang Y, Li Z, Wu H, Zou B, Xu Y. Exploring natural products as radioprotective agents for cancer therapy: Mechanisms, challenges, and opportunities. *Cancers* 2023; 15: 3585.
- [13] Lang DK, Singh H, Arora A, Arora R, Saini B, Arora S, et al. Radioprotectors: Nature's Boon. *Mini Rev Med Chem* 2021; 21: 3074–3096.
- [14] Ghebre YT. Proton pump inhibitors in IPF: A call for clinical trials. *Front Pharmacol* 2018; 9: 499.
- [15] Parcheta M, Świsłocka R, Orzechowska S, Akimowicz M, Choińska R, Lewandowski W. Recent developments in effective antioxidants: The structure and antioxidant properties. *Materials* 2021; 14: 1984.
- [16] Ping Zh, Peng Y, Lang H, Xinyong C, Zhiyi Z, Xiaocheng W, et al. Oxidative stress in radiation-induced cardiotoxicity. Oxid Med Cell Longev 2020; 2020: 3579143.
- [17] Nuszkiewicz J, Woźniak A, Szewczyk-Golec K. Ionizing radiation as a source of oxidative stress -the protective role of melatonin and vitamin D. *Int J Mol Sci* 2020; 21: 5804.
- [18] Bagheri H, Salajegheh A, Javadi A, Amini P, Shekarchi B, Shabeeb D, et al. Radioprotective effects of zinc and selenium on mice spermatogenesis. *J Biomed Phys Eng* 2020; 10: 707–712.
- [19] Ghebre Y, Raghu G. Proton pump inhibitors in IPF: Beyond mere suppression of gastric acidity. QJM 2016; 109: 577–579.
- [20] Canyilmaz E, Uslu GH, Bahat Z, Kandaz M, Mungan S, Haciislamoglu E, et al. Comparison of the effects of melatonin and genistein on radiation-induced nephrotoxicity: Results of an experimental study. *Biomed Rep* 2016; 4: 45–50.

- [21] Naeimi RA, Amiri FT, Khalatbary AR, Ghasemi A, Zargari M, Ghesemi M, et al. Atorvastatin mitigates testicular injuries induced by ionizing radiation in mice. *Reprod Toxicol* 2017; 72: 115–121.
- [22] Talebpour Amiri F, Raeispour M, Farzipour S, Hosseinimehr SJ. Radioprotective effect of febuxostat against testicular damage induced by ionizing radiation in mice. *Curr Radiopharm* 2022; 15: 134–140.
- [23] Fatehi D, Mohammadi M, Shekarchi B, Shabani A, Seify M, Rostamzadeh A. Radioprotective effects of Silymarin on the sperm parameters of NMRI mice irradiated with γ-rays. *J Photochem Photobiol B: Biology* 2018; 178: 489–495.
- [24] Shokri S, Soltani A, Kazemi M, Sardari D, Babapoor Mofrad F. Effects of Wi-Fi (2.45 GHz) exposure on apoptosis, sperm parameters and testicular histomorphometry in rats: A time course study. *Cell* J 2015; 17: 322.
- [25] Saghaei H, Mozdarani H, Mahmoudzadeh A. Sperm DNA damage in mice irradiated with various doses of X-rays alone or in combination with actinomycin D or bleomycin sulfate: An in vivo study. *Int J Radiat Res* 2019; 17: 317–323.
- [26] Geramizadeh B, Marzban M, Churg A. Role of immunohistochemistry in the diagnosis of solitary fibrous tumor: A review. *Iran J Pathol* 2016; 11: 195.
- [27] Li M, Yang L, Liu S, Chen L, Ma CC. Endocrine late effects of radiation therapy in pediatric and young adult patients with brain tumors. *Mathews J Cancer Sci* 2023; 8: 37.
- [28] Casano-Sancho P, Izurieta-Pacheco AC. Endocrine late effects in childhood cancer survivors. *Cancers* 2022; 14: 2630.
- [29] Ramirez-Fort MK, Rogers MJ, Santiago R, Mahase SS, Mendez M, Zheng Y, et al. Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (part I defining the organ at risk for sexual toxicities). *Rep Pract Oncol Radiother* 2020; 25: 367–375.
- [30] Oermann EK, Suy S, Hanscom HN, Kim JS, Lei S, Yu X, et al. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low-to intermediate-risk prostate cancer. *J Hematol Oncol* 2011; 4: 12.
- [31] Kil W, Nichols R, Hoppe B, Marcus R, Mendenhall W, Mendenhall N, et al. Hypofractionated proton radiation therapy for low-and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression. *Int J Radiat Oncol Biol Physic* 2012; 84: S375.
- [32] Hebert KA, Jaramillo S, Yu W, Wang M, Veeramachaneni R, Sandulache VC, et al. Esomeprazole enhances the effect of ionizing radiation to improve tumor control. *Oncotarget* 2021; 12: 1339.